|
Jul 22
|
NYC Council's Firewall Starts in District 5--with a Bombshell Named Alina
|
|
Jul 21
|
Sanofi (SNY) Expands Rare Disease Reach With $9.5B Blueprint Deal
|
|
Jul 21
|
SAB Biotherapeutics Raises $175 Million in Oversubscribed Private Placement; Shares Rise Pre-Bell
|
|
Jul 21
|
Sanofi concludes Blueprint Medicines acquisition
|
|
Jul 21
|
SAB BIO Announces Oversubscribed $175 Million Private Placement
|
|
Jul 20
|
Thermo Fisher Scientific (TMO) Announces Strategic Partnership Expansion With Sanofi
|
|
Jul 18
|
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
|
|
Jul 18
|
Adult-onset Still Disease Market Research Report 2025-2035 | Personalized Medicine and Biomarker Discoveries Enhance Treatment Outcomes
|
|
Jun 30
|
Sanofi (ENXTPA:SAN) Gains Orphan Drug Status In Japan For CIDP Treatment
|
|
Jun 30
|
Hedge Fund Strategy Built on Catastrophes Taps Hot New Trend
|
|
Jun 30
|
ESTEVE to acquire medicine to treat medullary thyroid cancer
|
|
Jun 30
|
Press release: Availability of the Q2 2025 Aide mémoire
|
|
Jun 30
|
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
|
|
Jun 27
|
Kymera’s partnerships with Sanofi and Gilead drive value
|
|
Jun 26
|
Kymera weakness a buying opportunity, says Stifel
|
|
Jun 26
|
Morning Movers: General Mills dips following fourth quarter report
|
|
Jun 26
|
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
|
|
Jun 26
|
Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
|
|
Jun 25
|
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
|
|
Jun 25
|
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi
|